• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2012 Product Image

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2012

  • ID: 2366399
  • December 2012
  • 178 pages
  • Global Markets Direct

Adenocarcinoma Of The Gastroesophageal Junction – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction. Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 7
REPORT COVERAGE 7
Adenocarcinoma Of The Gastroesophageal Junction Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction 9
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics under Development by Companies 11
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Pre-Clinical Stage Products 20
Comparative Analysis 20
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics – Products under Development by Companies 21
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Adenocarcinoma Of The Gastroesophageal Junction Therapeutics Development 27
F. Hoffmann-La Roche Ltd. 27
Amgen Inc. 28
Sanofi-Aventis 29
Eli Lilly and Company 30
GlaxoSmithKline plc 31
Millennium Pharmaceuticals, Inc. 32
Merck KGaA 33
Neogenix Oncology Corporation 34
GANYMED Pharmaceuticals AG 35
Merrimack Pharmaceuticals, Inc. 36
Mebiopharm Co., Ltd. 37
Adenocarcinoma Of The Gastroesophageal Junction – Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
trastuzumab emtansine - Drug Profile 44
alisertib - Drug Profile 47
ramucirumab - Drug Profile 49
irinotecan hydrochloride - Drug Profile 51
iMAB-362 - Drug Profile 53
Cisplatin + Fluorouracil + Iressa + Radiation Therapy - Drug Profile 54
Taxotere + Oxaliplatin + 5-Fluorouracil - Drug Profile 56
Epirubicin + Cisplatin + 5-Fluorouracil - Drug Profile 58
Irinotecan + Cisplatin + Bevacizumab - Drug Profile 59
saracatinib - Drug Profile 60
Tykerb + Capecitabine + Oxaliplatin - Drug Profile 61
Cisplatin + Epirubicin + Fluorouracil + Oxaliplatin + Radiation Therapy - Drug Profile 63
Docetaxel + Oxaliplatin + Capecitabine + Fluorouracil + Radiation Therapy - Drug Profile 65
sunitinib malate - Drug Profile 67
Cisplatin + Pemetrexed + Radiation Therapy - Drug Profile 68
capecitabine - Drug Profile 69
Sunitinib + Capecitabine - Drug Profile 70
Rilotumumab + Capecitabine + Epirubicin + Cisplatin - Drug Profile 72
XRP6976 + Oxaliplatin + S-1 - Drug Profile 74
IMC-1121B + mFOLFOX-6 - Drug Profile 76
Docetaxel + 5-Fluorouracil + Oxaliplatin - Drug Profile 78
oxaliplatin - Drug Profile 80
Docetaxel + Cisplatin + Fluorouracil + Bevacizumab + Leucovorin - Drug Profile 81
Epirubicin + Oxaliplatin + Capecitabine - Drug Profile 83
Docetaxel + Oxaliplatin - Drug Profile 85
Bevacizumab + Capecitabine + Carboplatin - Drug Profile 87
Epirubicin + Cisplatin + Fluorouracil + Lapatinib - Drug Profile 89
Epirubicin + Cisplatin + Capecitabine + Lapatinib - Drug Profile 91
aresenic trioxide - Drug Profile 93
Cisplatin + Irinotecan + Capecitabine - Drug Profile 94
FOLFOX - Drug Profile 95
FOLFOX + GDC-0449 - Drug Profile 97
Capecitabine + Oxaliplatin + Radiation Therapy - Drug Profile 99
Docetaxel + Oxaliplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 101
Docetaxel + 5-Fluorouracil + Oxaliplatin + Folinic Acid - Drug Profile 103
Docetaxel + Bevacizumab - Drug Profile 105
Cisplatin + Irinotecan + Floxuridine + Capecitabine - Drug Profile 106
AMG-386 + Cisplatin + Capecitabine - Drug Profile 107
Epirubicin + Cisplatin + Capecitabine + Bevacizumab + Docetaxel + Irinotecan - Drug Profile 109
5-Fluorouracil + Folinic Acid + Oxaliplatin - Drug Profile 111
MBP426 + Leucovorin + 5-Fluorouracil - Drug Profile 113
Cisplatin + Docetaxel + Panitumumab - Drug Profile 115
Panitumumab + Paclitaxel + Carboplatin + 5-Fluorouracil - Drug Profile 116
Pralatrexat + Oxaliplatin - Drug Profile 118
FOLFOX - Drug Profile 120
Docetaxel + Oxaliplatin + Folinic Acid + Fluorouracil - Drug Profile 122
Docetaxel + Capacitabine - Drug Profile 124
Lapatinib + Capecitabine - Drug Profile 126
Oblimersen Sodium + Cisplatin + 5-Fluorouracil - Drug Profile 127
Xeloda + Docetaxel + Cisplatin - Drug Profile 129
Irinotecan + Alvocidib - Drug Profile 131
Carboplatin + Paclitaxel - Drug Profile 132
capecitabine - Drug Profile 134
Capecitabine + Cisplatin + Epirubicin Hydrochloride + Fluorouracil + Lapatinib Ditosylate - Drug Profile 135
Leucovorin Calcium + Cisplatin + Fluorouracil + Cetuximab - Drug Profile 137
Bryostatin 1 + Taxol - Drug Profile 139
Fluorouracil + Leucovorin Calcium + Oxaliplatin - Drug Profile 140
Irinotecan + Docetaxel - Drug Profile 142
mFOLFOX6 + Everolimus - Drug Profile 143
Oxaliplatin + Sorafenib - Drug Profile 145
Panitumumab + Epirubicin + Cisplatin + Capecitabine - Drug Profile 146
Epirubicin + Cisplatin + Fluorouracil - Drug Profile 148
Docetaxel + Oxaliplatin + Capecitabine - Drug Profile 150
NEO-301 - Drug Profile 151
Cetuximab + TS-1 + Cisplatin - Drug Profile 153
Pertuzumab + Herceptin + Cisplatin + Capecitabine - Drug Profile 155
5-Fluorouracil + Leucovorin + Docetaxel + Oxaliplatin + Trastuzumab - Drug Profile 157
paclitaxel - Drug Profile 159
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics – Drug Profile Updates 160
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics – Discontinued Products 169
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics - Dormant Products 170
Appendix 173
Methodology 173
Coverage 173
Secondary Research 173
Primary Research 173
Expert Panel Validation 173
Contact Us 174
Disclaimer 174

List of Tables
Number of Products Under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2012 13
Products under Development for Adenocarcinoma Of The Gastroesophageal Junction – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Investigation by Universities/Institutes, H2 2012 18
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 19
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 20
Comparative Analysis by Late Stage Development, H2 2012 21
Comparative Analysis by Mid Clinical Stage Development, H2 2012 22
Comparative Analysis by Early Clinical Stage Development, H2 2012 23
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 24
Products under Development by Companies, H2 2012 25
Products under Development by Companies, H2 2012 (Contd..1) 26
Products under Investigation by Universities/Institutes, H2 2012 27
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 28
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 29
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 30
F. Hoffmann-La Roche Ltd., H2 2012 31
Amgen Inc., H2 2012 32
Sanofi-Aventis, H2 2012 33
Eli Lilly and Company, H2 2012 34
GlaxoSmithKline plc, H2 2012 35
Millennium Pharmaceuticals, Inc., H2 2012 36
Merck KGaA, H2 2012 37
Neogenix Oncology Corporation, H2 2012 38
GANYMED Pharmaceuticals AG, H2 2012 39
Merrimack Pharmaceuticals, Inc., H2 2012 40
Mebiopharm Co., Ltd., H2 2012 41
Assessment by Monotherapy Products, H2 2012 42
Assessment by Combination Products, H2 2012 43
Assessment by Stage and Route of Administration, H2 2012 45
Assessment by Stage and Molecule Type, H2 2012 47
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics – Drug Profile Updates 164
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics – Discontinued Products 173
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics – Dormant Products 174
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics – Dormant Products (Contd..1) 175
Adenocarcinoma Of The Gastroesophageal Junction Therapeutics – Dormant Products (Contd..2) 176

List of Figures
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2012 13
Products under Development for Adenocarcinoma Of The Gastroesophageal Junction – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 17
Late Stage Products, H2 2012 21
Mid Clinical Stage Products, H2 2012 22
Early Clinical Stage Products, H2 2012 23
Pre-Clinical Stage Products, H2 2012 24
Assessment by Monotherapy Products, H2 2012 42
Assessment by Combination Products, H2 2012 43
Assessment by Route of Administration, H2 2012 44
Assessment by Stage and Route of Administration, H2 2012 45
Assessment by Molecule Type, H2 2012 46
Assessment by Stage and Molecule Type, H2 2012 47

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos